MIRA Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices)
Registrant’s
telephone number, including area code:
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), or MIRA, today announced a key development milestone that may significantly advance the Company’s topical drug pipeline: its novel topical formulation of Ketamir-2 demonstrated successful, dose-proportional drug release in a validated laboratory study, marking a critical step forward in the program’s progression toward clinical testing.
The results of the in vitro release testing (IVRT) confirm that Ketamir-2 can be delivered reliably and consistently through a topical cream—a challenge that many water-soluble compounds fail to overcome when formulated in hydrophobic bases. This breakthrough provides MIRA with a new opportunity to pursue localized, non-opioid pain treatment options that may complement its oral Ketamir-2 formulation currently in Phase 1 trials.
“This is not just a formulation milestone—it’s a strategic inflection point,” said Erez Aminov, Chairman and CEO of MIRA. “With both oral and topical path now in motion, we’re targeting a much broader market and moving closer to providing multiple therapeutic options to address the growing burden of pain.”
MIRA is now initiating preclinical efficacy studies to assess whether the topical formulation can offer therapeutic effects in models of inflammatory and neuropathic pain. These studies are expected to provide data to guide potential clinical advancement.
MIRA is also evaluating whether the topical Ketamir-2 program may meet the criteria for Fast Track designation under the United States Food and Drug Administration (“FDA”)’s expedited development program for serious conditions. If granted, Fast Track status could facilitate closer communication with the FDA and potentially accelerate the path to first-in-human studies.
The potential significance of this development is further underscored by the market opportunity it addresses. According to The Business Research Company, the U.S. topical pain relief market is projected to exceed $11.5 billion in 2025, driven by increased demand for non-opioid, localized therapies that minimize systemic exposure. MIRA believes its dual-route Ketamir-2 strategy is uniquely positioned to engage both systemic and topical treatment markets.
MIRA’s oral Ketamir-2 formulation is currently being evaluated in a Phase 1 clinical trial, with a Phase 2a trial in diabetic neuropathy expected to commence later this year.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MIRA PHARMACEUTICALS, INC. | ||
| Dated: April 23, 2025 | By: | /s/ Erez Aminov |
| Name: | Erez Aminov | |
| Title: | Chief Executive Officer | |